Neuroveda Podcast for Complex Health #76 Paul S. Malchesky, D.Eng., on Plasmapheresis: history, technology and potential benefit for deep disease & longevity
Dr Paul Malchesky, with a Master’s degree in Chemistry and a Doctorate in Engineering, has been working with apheresis since the 1970’s. This is a blood filtration or ‘cleaning’ therapy we offer at Neuroveda Health as plasmapheresis (also called plasma exchange, PLEX and TPE (total or therapeutic plasma exchange)). There’s been a lot of recent excitement regarding treatment of Long-COVID and as a ‘biohack’ for longevity, but the truth is that it’s been nearly half a century since the FDA approved this therapy for auto-immune and neurodegenerative conditions. The technology has come a long way and Dr Malchesky has been there the whole time. Of note, Ayurveda, the traditional medical system of India, also recognizes the value of detox and blood cleansing, making plasmapheresis a type of ‘rakta moksha’. This is a modern tool with ancient roots, our favorite kind of therapy. Today, we get into the history and mechanics to describe what this therapy is doing and how broad it’s use can be.
We discuss:
· 3:30 What is apheresis?
· 4:19 What is the history of apheresis?
· 11:56 What is in blood? What are the components of blood?
· 13.20 About anti-coagulation
· 15:53 Ayurvedic use of blood cleansing called ‘rakta moksa’
· 18:06 Dr Malchesky’s personal history with apheresis starting with 1972; Reporting up to 40 diseases treated by 1981.
· 24:40 Comparison of dialysis vs plasmapheresis filtration
· 29:00 Late 70’s/ early 80’s, efforts to identify the specific proteins associated with certain diseases; findings and curiosity about cryoproteins- precipitates triggered by cold.
· 36:57 Treatment to remove high cholesterol to prevent atherosclerosis.
· 40:29 Description of the last 15 years of apheresis: applications & guidelines have really diversified by geography (centripetal in US & German; membrane for Japan), technology and disease state
· 42:58 Safety of this procedure
· 43:52 Difficulties with this procedure are most typically associated with venous access and sometimes blood pressure changes and/or anti-coagulant use
· 44:40 Recognition that the macromolecules produced as ‘toxic’ can present in every silo of medicine: oncology, rheumatology, neurology, and therefore, also make sense to use these treatments for longevity & anti-aging
· 49:43 In studying the toxins removed, it’s evident that these toxins removed impair cellular function, so removal can allow cells to perform more of their regular functions.
· 51:08 The goal at Neuroveda Health is that plasmapheresis is part of a larger medical and wellness program to renovate the health from the ground up.
· 51:38 Discussion of Lp(a).
· 53:24 Designing clinical trials using historical experience of the questions and initial clinical trial endeavors with rheumatoid arthritis patients
BIO: Dr. Paul Malchesky holds a B.S. Degree in Chemistry from St. Francis University, M.S. degrees in Chemistry from Case Western Reserve University and in Chemical Engineering from Cleveland State University and a Doctorate in Engineering from Cleveland State University. He is President of the International Center for Artificial Organs and Transplantation (ICAOT) and consults for the chemical and medical industries.
He has published extensively nearly 500 publications, holds 35 patents, and was co-editor of four books on apheresis. He is active in various professional societies and is the former Editor-in-Chief of Artificial Organs and Managing Editor of Therapeutic Apheresis and Dialysis. He is a Past-President of the International Society for Apheresis. He is an Elected Fellow to the American Institute for Medical and Biological Engineering and The Ohio Academy of Science.
Recently he developed the web site icaot.org that discusses the history of the International Center for Artificial Organs & Transplantation and includes Milestones in the field and invites contributions to its Virtual Collection.